Immunotherapy

A new study identifies the protein SLFN5 as a key barrier to effective treatment in Pancreatic Ductal Adenocarcinoma (PDAC). SLFN5 acts as an “intracellular immune checkpoint,” helping tumors remain “cold” by evading immune attack and resisting standard therapies. High levels of SLFN5 are linked to poor patient survival. While Interferons normally activate anti-tumor defenses, SLFN5 […]

The phase 3 SUCCESSOR-2 trial has shown that adding Mezigdomide to a treatment combination of Carfilzomib and Dexamethasone significantly improves progression-free survival in patients with relapsed or refractory Multiple Myeloma. The study included patients who had received at least one previous line of therapy, including treatment with Lenalidomide and anti-CD38 antibodies, a group that often

ImmunityBio has resubmitted a supplemental biologics license application to the U.S. Food and Drug Administration seeking approval for Nogapendekin alfa inbakicept-pmln (Anktiva) to treat patients with BCG-unresponsive, non-muscle-invasive bladder cancer who have papillary-only tumors. The FDA had previously issued a refusal-to-file letter in May 2025, but after a January 2026 meeting the agency requested updated

Researchers have discovered that advanced tumors can manipulate the metabolism of erythroid progenitor cells (EPCs), a type of immature red blood cell, to suppress the body’s immune response. In many cancer patients, tumors stimulate the production of these cells outside the bone marrow, mainly in the spleen. Some EPCs enter the tumor microenvironment where they

A study reports long-term results from the CCTG PA.7 phase II trial testing whether adding immunotherapy to chemotherapy improves outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial evaluated the combination of durvalumab and tremelimumab with standard chemotherapy (gemcitabine and nab-paclitaxel). Overall, the addition of immunotherapy did not significantly improve survival in the

Researchers have created a first-of-its-kind Digital Immune Atlas to tackle pancreatic cancer, a disease long resistant to immunotherapy. By analyzing over a decade of clinical trial samples from 64 patients, the team mapped how the immune system responds to treatments like vaccines (GVAX, CRS-207) and checkpoint inhibitors (anti-PD-1, anti-CTLA-4). The atlas revealed that even when

Scientists have created a new type of immunotherapy that fights metastatic cancer by attacking the tumor’s protective cells instead of the cancer cells themselves. This approach is designed to overcome the resistance seen in many solid tumors such as lung and ovarian cancer. Solid tumors often surround themselves with tumor-associated macrophages—immune cells that are reprogrammed

Researchers have created a new type of immunotherapy that turns the body’s own immune cells into cancer-fighting cells directly inside the tumor, without needing lab-based cell engineering. Solid tumors such as lung or liver cancer are hard to treat because they form dense tissue that blocks immune cells. They also weaken nearby macrophages, stopping them

Researchers have discovered a new way to make immunotherapy work against pancreatic cancer by targeting so-called cryptic peptides. These peptides come from parts of DNA that normally do not make proteins, sometimes called the “dark genome.” Cancer cells, however, often use these regions, creating abnormal peptides that do not appear in healthy tissue. The researchers

Researchers at Rockefeller University have uncovered how T cells switch from rest to attack, revealing a previously hidden motion in T cell receptors that helps explain how the immune system recognizes and responds to cancer. Using advanced cryo-electron microscopy, the team found that the T cell receptor normally stays tightly closed and inactive. When it